

# NEW ZEALAND DATA SHEET

## 1. PRODUCT NAME

NIMENRIX<sup>®</sup> injection with diluent.

Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine.

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

After reconstitution, 1 dose (0.5 mL) contains:

Meningococcal polysaccharide - Group A <sup>1</sup>	5 micrograms
Meningococcal polysaccharide - Group C <sup>1</sup>	5 micrograms
Meningococcal polysaccharide - Group W-135 <sup>1</sup>	5 micrograms
Meningococcal polysaccharide - Group Y <sup>1</sup>	5 micrograms

<sup>1</sup>conjugated to tetanus toxoid carrier protein 44 micrograms

For the full list of excipients (see Section 6.1 List of excipients).

## 3. PHARMACEUTICAL FORM

NIMENRIX is supplied as a white powder in a glass vial, together with a clear and colourless solvent supplied in a pre-filled syringe or ampoule.

## 4. CLINICAL PARTICULARS

### 4.1 Therapeutic Indications

NIMENRIX is indicated for active immunisation of individuals from 6 weeks of age against invasive meningococcal diseases caused by *Neisseria meningitidis* groups A, C, W-135 and Y.

### 4.2 Dose and Method of Administration

#### Dosage

NIMENRIX should be used in accordance with available official recommendations.

<b>Age Group</b>	<b>Primary Immunisation</b>	<b>Booster</b>
Infants from 6 weeks to less than 6 months of age* <sup>1,2</sup>	Two doses, each of 0.5 ml, with the first dose given from 6 weeks of age, with an interval of 2 months between doses	At 12 months of age
Unvaccinated infants from 6 months to less than 12 months of age**	One dose of 0.5 ml given from 6 months of age	At 12 months of age with a minimum interval of at least 2 months after the primary dose
Children from 12 months of age, adolescents and adults**	One dose of 0.5 ml	Not routinely administered

\* See Section 5.1 Pharmacodynamic properties for further information.

\*\*In some situations, consideration may be given to administering an additional primary dose or a booster dose of NIMENRIX (see Section 4.4 Special warnings and precautions for use and Section 5.1 Pharmacodynamic properties for further information).

NIMENRIX may be given as a booster dose to individuals who have previously received primary vaccination with NIMENRIX or other conjugated or plain polysaccharide meningococcal vaccines (see Sections 4.4 Special warnings and precautions for use and 5.1 Pharmacodynamic properties).

### ***Special populations***

Individuals who have underlying conditions predisposing them to meningococcal infection due to anatomic or functional asplenia (such as sickle cell disease) may receive at least one dose of Nimenrix (see Sections 4.8 Undesirable effects and 5.1 Pharmacodynamic properties).

### **Method of administration**

NIMENRIX is for single use in one patient only.

NIMENRIX is for intramuscular injection only.

The injection sites are the anterolateral aspect of the thigh in infants, or the anterolateral aspect of the thigh or deltoid muscle in individuals from 1 year of age (see Sections 4.4 Special warnings and precautions for use and 4.5 Interactions with other medicines and other forms of interaction).

For instructions on reconstitution of the vaccine before administration (see Section 6.6 Special precautions for disposal and other handling).

## **4.3 Contraindications**

NIMENRIX should not be administered to subjects with hypersensitivity to the active substances or to any of the excipients contained in the vaccine.

## **4.4 Special Warnings and Precautions for Use**

NIMENRIX should under no circumstances be administered intravascularly, intradermally or subcutaneously.

It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable effects) and a clinical examination.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.

### **Intercurrent illness**

As with other vaccines, NIMENRIX should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

### **Syncope**

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.

### **Thrombocytopenia and coagulation disorders**

As with other vaccines administered intramuscularly, NIMENRIX should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.

### **Immunodeficiency**

It may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate immune response may not be elicited.

Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example eculizumab) are at increased risk for invasive disease caused by *Neisseria meningitidis* groups A, C, W-135 and Y even if they develop antibodies following vaccination with NIMENRIX.

### **Special populations**

Safety and immunogenicity data are available for a limited number of patients with increased susceptibility to meningococcal infection due to anatomic or functional asplenia (such as sickle cell disease). See Sections 4.2 Dose and method of administration, 4.8 Undesirable effects, and 5.1 Pharmacodynamic properties.

### **Protection against meningococcal disease**

NIMENRIX will only confer protection against *Neisseria meningitidis* groups A, C, W-135 and Y. The vaccine will not protect against other *Neisseria meningitidis* groups.

As with any vaccine, a protective immune response may not be elicited in all vaccine recipients.

### **Immune response in infants aged 6 months to less than 12 months**

A single-dose administered at 6 months was associated with lower human complement serum bactericidal assay (hSBA) titres to groups W-135 and Y compared with three doses administered at 2, 4, and 6 months (see Section 5.1 Pharmacodynamic properties). The clinical relevance of this finding is unknown. If an infant aged 6 months to less than 12 months is expected to be at immediate risk of invasive meningococcal disease due to exposure to groups W-135 and Y, consideration may be given to administering a second primary dose of NIMENRIX after an interval of 2 months.—

### **Immune responses in toddlers aged 12-14 months**

At one month post vaccination, toddlers aged 12-14 months had similar rabbit complement serum bactericidal assay (rSBA) responses to groups A, C, W-135 and Y following one dose of NIMENRIX or two doses of NIMENRIX given two months apart. At one year post vaccination, the rSBA responses for groups A, C, W-135 and Y were similar in both the one and the two dose groups (see Section 5.1 Pharmacodynamic properties).

Measured with hSBA, 1 month post vaccination, responses to groups W-135 and Y were lower after a single dose than after 2 doses given two months apart, while responses to groups A and C were similar in the two groups (see Section 5.1 Pharmacodynamic properties). At one year post vaccination, the hSBA responses for groups A, C, W-135 and Y were similar in both the one and the two dose groups (see Section 5.1 Pharmacodynamic properties). The clinical relevance of the findings is unknown. If a toddler is expected to be at particular risk of invasive meningococcal disease due to exposure to groups W-135 and Y, consideration may be given to administering a second dose after an interval of 2 months. Regarding waning of antibody against MenA or MenC after a first dose of NIMENRIX in children aged 12-23 months, see under Persistence of serum bactericidal antibody titres.

### **Persistence of serum bactericidal antibody titres**

Persistence of antibodies has been evaluated up to 5 years after vaccination. The persistence studies with NIMENRIX have shown a waning of serum bactericidal antibody titres against MenA when using hSBA (see Section 5.1, Pharmacodynamic properties). The clinical relevance of the waning of hSBA-MenA antibody titres is unknown. Currently there is limited information available on the safety of a booster dose. However, if an individual is expected to be at particular risk of exposure to MenA and received a dose of NIMENRIX more than approximately one year previously, consideration may be given to administering a booster dose.

Similar to the monovalent Men C comparator, a decline in antibody titres over time has been observed. The clinical significance of the waning antibody titres is unknown. A booster dose might be considered in individuals remaining at high risk of exposure to meningococcal disease caused by groups A, C, W-135 and Y (see Section 5.1, Pharmacodynamic properties).

Although NIMENRIX contains tetanus toxoid, this vaccine does not substitute for tetanus immunisation.

### **Paediatric population**

See Sections 4.1 Therapeutic indications; 4.2 Dose and method of administration; 4.4 Special warnings and precautions for use (see under Protection against meningococcal disease); 4.5 Interactions with other medicines and other forms of interactions; 4.8 Adverse effects and 5.1 Pharmacodynamic properties.

## Elderly population

There are no data available.

## 4.5 Interactions with Other Medicines and Other Forms of Interaction

In infants, NIMENRIX can be given concomitantly with combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccines, as well as 10-valent pneumococcal conjugate vaccine.

From age 1 year and above, NIMENRIX can be given concomitantly with any of the following vaccines: hepatitis A (HAV) and hepatitis B (HBV) vaccines, measles-mumps-rubella (MMR) vaccine, measles-mumps-rubella-varicella (MMRV) vaccine, 10-valent pneumococcal conjugate vaccine or unadjuvanted seasonal influenza vaccine.

NIMENRIX can also be given concomitantly with combined diphtheria-tetanus-acellular pertussis (DTaP) vaccines, including combination DTaP vaccines with hepatitis B, inactivated poliovirus (IPV) or Haemophilus influenzae type b (Hib), such as DTaP-HBV-IPV/Hib vaccine and 13-valent pneumococcal conjugate vaccine in the second year of life.

In individuals aged 9 to 25 years, NIMENRIX can be given concomitantly with human papillomavirus bivalent [Type 16 and 18] recombinant vaccine (HPV2).

Safety and immunogenicity of NIMENRIX was evaluated when sequentially administered or co-administered with a DTaP-HBV-IPV/Hib vaccine in the second year of life. The administration of NIMENRIX one month after the DTaP-HBV-IPV/Hib vaccine resulted in lower MenA, MenC and MenW-135 GMTs as measured with rSBA. Clinical relevance of this observation is unknown, since at least 99.4% of subjects (N=178) had rSBA titres  $\geq 8$  for each group (A, C, W-135, Y). Whenever possible, NIMENRIX and a tetanus toxoid (TT) containing vaccine, such as DTaP-HBV-IPV/Hib vaccine, should be co-administered or NIMENRIX should be administered at least one month before the TT-containing vaccine.

One month after co-administration with a combined TT-containing vaccine, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Tdap) in subjects aged 9 to 25 years, lower Geometric Mean antibody Concentrations (GMCs) were observed to each pertussis antigen (pertussis toxoid[PT], filamentous haemagglutinin [FHA] and pertactin [PRN]). More than 98% of subjects had anti-PT, FHA or PRN concentrations above the assay cut-off thresholds. The clinical relevance of these observations is unknown. There was no impact of co-administration on immune responses to NIMENRIX or the tetanus or diphtheria antigens included in Tdap.

One month after co-administration with a 10-valent pneumococcal conjugate vaccine in toddlers aged 12 to 23 months, lower GMCs and opsonophagocytic assay (OPA) antibody GMTs were observed for one pneumococcal serotype (18C conjugated to tetanus toxoid carrier protein). Clinical relevance of this observation is unknown. There was no impact of co-administration on the other nine pneumococcal serotypes.

If NIMENRIX is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.

As with other vaccines it may be expected that in patients receiving immunosuppressive treatment an adequate response may not be elicited.

## **4.6 Fertility, Pregnancy and Lactation**

### **Pregnancy**

Pregnancy Category B2

There is limited experience with use of NIMENRIX in pregnant women.

Animal studies with NIMENRIX do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development (see Section 5.3 Preclinical safety data).

NIMENRIX should be used during pregnancy only when clearly needed, and the possible advantages outweigh the potential risks for the foetus.

### **Breast-feeding**

The safety of NIMENRIX when administered to breastfeeding women has not been evaluated. It is unknown whether NIMENRIX is excreted in human breast milk.

NIMENRIX should only be used during breast-feeding when the possible advantages outweigh the potential risks.

### **Fertility**

Animal studies with NIMENRIX do not indicate direct or indirect harmful effects with respect to fertility (see Section 5.3 Preclinical safety data).

## **4.7 Effects on Ability to Drive and Use Machines**

No studies on the effects of NIMENRIX on the ability to drive and use machines have been performed.

## **4.8 Undesirable Effects**

### **Clinical Trial Data**

The safety of NIMENRIX presented in the table below is based on two clinical study datasets as follows:

- A pooled analysis of data from 9,621 subjects administered a single dose of NIMENRIX. This total included 3,079 toddlers (12 months to 23 months), 909 children between 2 and 5 years of age, 990 children between 6 and 10 years of age, 2,317 adolescents (11 to 17 years) and 2,326 adults (18 to 55 years). In a separate study a single dose of NIMENRIX was administered to 274 individuals aged 56 years and older.
- Data from a study in infants aged 6 to 12 weeks at the time of the first dose (Study MenACWY-TT-083), 1,052 subjects received at least one dose of a primary series of 2 or 3 doses of NIMENRIX and 1,008 received a booster dose at approximately 12 months of age.

In an additional clinical study of age matched subjects who were either healthy or at increased risk of meningococcal disease due to anatomical or functional asplenia (such as sickle cell disease), the safety profile of NIMENRIX in at-risk children and adolescents was generally similar to that observed in the non-asplenic population (see Section 5.1 Pharmacodynamic properties).

## **Local and general adverse reactions**

In all age groups, the local adverse reactions of pain, redness and swelling at the injection site were reported at a very common frequency after vaccination.

In the infant and toddler groups, the general adverse reactions of drowsiness, fever, irritability/fussiness and loss of appetite were reported at a very common frequency after vaccination.

In a separate infant study, 554 infants were primed with 1 or 3 doses of NIMENRIX and 508 received booster doses in the second year of life. Local and general adverse reactions in this study were similar in frequency to the larger infant study.

In the 12-14 months age group who received 2 doses of NIMENRIX given 2 months apart, the first and second doses were associated with similar local and systemic reactogenicity.

The 2–5 year group reported general adverse reactions at a frequency ranging from common (irritability, loss of appetite and fever) to very common (drowsiness).

In the 6-10, 11-17 and  $\geq 18$  years age groups, the general adverse reactions were reported at a frequency ranging from common (gastrointestinal symptoms and fever) to very common (headache and fatigue).

### **Adverse reactions reported are listed according to the following frequency:**

Very common	$\geq 1/10$
Common	$\geq 1/100$ to $< 1/10$
Uncommon	$\geq 1/1,000$ to $< 1/100$
Rare	$\geq 1/10,000$ to $< 1/1,000$
Very rare	$< 1/10,000$
Unknown (cannot be estimated from the available data)	

### ***Metabolism and nutrition disorders***

Very common: appetite lost

### ***Psychiatric disorders***

Very common: irritability  
Uncommon: insomnia, crying

### ***Nervous system disorders***

Very common: drowsiness, headache  
Uncommon: hypoaesthesia, dizziness

### ***Gastrointestinal disorders***

Common: gastrointestinal symptoms (including diarrhoea, vomiting and nausea\*)

### ***Skin and subcutaneous tissue disorders***

Uncommon: pruritus, rash\*\*

### ***Musculoskeletal and connective tissue disorders***

Uncommon: myalgia, pain in extremity

### ***General disorders and administration site conditions***

Very common: fever, swelling, pain and redness at injection site, fatigue

Common: injection site haematoma\*

Uncommon: malaise, injection site reaction (including induration, pruritus, warmth, anaesthesia)

\*Nausea and injection site haematoma occurred at a frequency of Uncommon in infants

\*\*Rash occurred at a frequency of Common in infants

The adverse reactions headache, hypoaesthesia, dizziness, pruritus, myalgia, pain in extremity and fatigue were not reported in the infant clinical study.

## **Post-Marketing Data**

### ***General disorders and administration site conditions***

Unknown: extensive limb swelling at the injection site, frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb.

### ***Reporting of suspected adverse reactions***

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <http://nzphvc.otago.ac.nz/reporting/>.

## **4.9 Overdose**

No cases of overdose have been reported.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic Properties**

Pharmacotherapeutic Group: bacterial vaccines, ATC code J07AH08.

#### **Mechanism of Action**

Anti-capsular meningococcal antibodies protect against meningococcal diseases via complement mediated bactericidal activity. NIMENRIX induces the production of bactericidal antibodies against capsular polysaccharides of serogroups A, C, W-135 and Y when measured by serum bactericidal antibody assays (SBA) using either rSBA or hSBA.

By conjugating capsular polysaccharide to a protein carrier that contains T-cell epitopes, meningococcal conjugate vaccines like NIMENRIX change the nature of the immune response to capsular polysaccharide from T-cell independent to T-cell dependent.

## **CLINICAL TRIALS**

### **Immunogenicity**

The immunogenicity of one dose of NIMENRIX has been evaluated in more than 8,000 subjects from 12 months of age and in approximately 1000 subjects below 12 months of age.



Vaccine efficacy was inferred from the demonstration of immunologic non-inferiority compared to licensed meningococcal vaccines. Immunogenicity was measured by rSBA or hSBA which are biomarkers for protective efficacy against meningococcal groups A, C, W-135 and Y.

The vaccine response was defined in clinical studies as:

#### rSBA

- Toddlers aged 12-23 months: rSBA  $\geq$  1:8
- Children aged  $>$  2 years, adolescents and adults: rSBA  $\geq$  1:32 for initially seronegative subjects; or at least a 4-fold increase in rSBA titres from pre- to post-vaccination for initially seropositive subjects

#### hSBA

- At least a 2-fold increase in hSBA titre (i.e hSBA  $\geq$ 1:8) from pre- to post-vaccination for initially seronegative subjects of all ages
- At least a 4-fold increase in hSBA titre from pre- to post-vaccination for initially seropositive subjects of all ages.

### **Vaccine Immunogenicity**

#### **Booster Response**

In 5 clinical trials, the use of NIMENRIX as a booster following primary vaccination with NIMENRIX or other meningococcal vaccines (quadrivalent meningococcal A, C, W-135, and Y DT conjugate vaccine or monovalent MenC conjugate vaccines) was evaluated. A robust NIMENRIX booster response was observed for all groups in all age ranges assessed.

#### **Infants**

##### *Immunogenicity in infants*

Two clinical studies have been conducted in infants, MenACWY-TT-083 and MenACWY-TT-087. In MenACWY-TT-083, the immunogenicity of a 2-dose primary vaccination schedule administered at 2 and 4 months of age was evaluated (Table 1). Routinely used infant vaccines DTPa-HBV-IPV/Hib and a 10-valent pneumococcal vaccine were co-administered. For group C, the immune response elicited by NIMENRIX was compared to a 2-dose priming with licensed monovalent meningococcal conjugate group C vaccines, C-CRM197 conjugate (MenC-CRM) and C-TT conjugate (MenC-TT) vaccines. NIMENRIX elicited a bactericidal antibody response against the four groups. The response against group C was non-inferior to the one elicited by the licensed MenC-CRM and MenC-TT vaccines in term of rSBA titres  $\geq$ 8.

For subjects primed in infancy with NIMENRIX at 2 and 4 months of age and receiving a NIMENRIX booster dose at 12 months of age, the increase in rSBA and hSBA titres one month post-booster dose ranged between 15 and 80-fold for all groups and more than 99.0% of all infants achieved post-booster titres above 8 for both assays (Table 1). The observed booster response for MenC was similar to that observed in subjects primed and boosted with a monovalent MenC conjugate vaccine (TT or CRM conjugated).

**Table 1: Bactericidal antibody responses in infants after priming and after a booster dose**

Group	Response to		Study MenACWY-TT-083 (2-dose priming) rSBA*			Study MenACWY-TT-083 (2-dose priming) hSBA**		
			N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	NIMENRIX	Post dose 2	456	97.4% (95.4; 98.6)	203 (182; 227)	202	96.5% (93.0; 98.6)	157 (131; 188)
		Booster dose	462	99.6% (98.4; 99.9)	1561 (1412.3; 11725.3)	214	99.5% (97.4; 100)	1007.2 (835.7; 1213.8)
C	NIMENRIX	Post dose 2	456	98.7% (97.2; 99.5)	612 (540; 693)	218	98.6% (96.0; 99.7)	1308 (1052; 1627)
		Booster dose	463	99.8% (98.8; 100)	1177 (1059.1; 1308)	221	99.5% (97.5; 100)	4992.3 (4085.7; 6100)
	MenC-CRM vaccine	Post dose 2	455	99.6% (98.4; 99.9)	958 (850; 1079)	202	100% (98.2; 100)	3188 (2646; 3841)
		Booster dose	446	98.4% (96.8; 99.4)	1051.4 (919.6; 1201.1)	216	100% (98.3; 100)	5438.2 (4412.4; 6702.3)
	MenC-TT vaccine	Post dose 2	457	100% (99.2; 100)	1188 (1080; 1307)	226	100% (98.4; 100)	2626 (2219; 3109)
		Booster dose	459	100% (99.2; 100)	1960.2 (1776.4; 2163.1)	219	100% (98.3; 100)	5542.3 (4765.2; 6446.2)
W	NIMENRIX	Post dose 2	455	99.1% (97.8; 99.8)	1605 (1383; 1862)	217	100% (98.3; 100)	753 (644; 882)
		Booster dose	462	99.8% (98.8; 100)	2777.2 (2485.1; 3103.6)	218	100% (98.3; 100)	5122.7 (4504.2; 5826.1)
Y	NIMENRIX	Post dose 2	456	98.2% (96.6; 99.2)	483 (419; 558)	214	97.7% (94.6; 99.2)	328 (276; 390)
		Booster dose	462	99.4% (99.1; 99.9)	881.3 (787.5; 986.4)	217	100% (98.3; 100)	2954 (2497.9; 3493.3)

The analysis of immunogenicity was conducted on the primary according-to-protocol (ATP) cohort for immunogenicity.

\*rSBA testing performed at Public Health England (PHE) laboratories in UK

\*\*hSBA tested at GSK laboratories

In MenACWY-TT-087, infants received either a single primary dose at 6 months followed by a booster dose at 15-18 months or three primary doses at 2, 4, and 6 months followed by a booster dose at 15-18 months. All subjects also received DTPa-IPV/Hib and 10-valent pneumococcal conjugate vaccines at all time points. A single primary dose administered at 6 months of age elicited robust rSBA responses to groups A, C, W-135 and Y, as measured by the percentage of subjects with rSBA titres  $\geq 8$ , that were comparable to responses after the last dose of a three-dose primary series. A booster dose produced robust responses, comparable between the two dosing groups, against all four meningococcal groups (Table 2).

**Table 2: Bactericidal antibody responses (rSBA\*) and (hSBA\*\*) in infants after one dose at 6 months of age and after a booster dose at 15-18 months of age (Study MenACWY-TT-087)**

Meningo-coccal Group		rSBA*			hSBA**		
		N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	Post dose 1 <sup>(1)</sup>	163	98.8% (95.6; 99.9)	1332.9 (1035.2; 1716.2)	59	98.3% (90.9; 100)	270.5 (205.9; 355.4)
	Pre Booster	131	81.7% (74.0; 87.9)	125.3 (84.4; 186.1)	71	66.2% (54.0; 77.0)	20.8 (13.5; 32.2)
	Post booster <sup>(1)</sup>	139	99.3% (96.1; 100)	2762.3 (2310.3; 3302.8)	83	100% (95.7; 100)	1415.6 (1140.2; 1757.5)
C	Post dose 1 <sup>(1)</sup>	163	99.4% (96.6; 100)	591.6 (482.3; 725.8)	66	100% (94.6; 100)	523.1 (381.5; 717.3)
	Pre Booster	131	65.6% (56.9; 73.7)	27.4 (20.6; 36.6)	78	96.2% (89.2; 99.2)	150.8 (108.5; 209.5)
	Post booster <sup>(1)</sup>	139	99.3% (96.1; 100)	2525.2 (2102.1; 3033.3)	92	100% (96.1; 100)	13360.1 (10952.9; 16296.4)
W	Post dose 1 <sup>(1)</sup>	163	93.9% (89.0; 97.0)	1255.9 (917.0; 1720.0)	47	87.2% (74.3; 95.2)	136.5 (78.4; 237.6)
	Pre Booster	131	77.9% (69.8; 84.6)	63.3 (45.6; 87.9)	53	100% (93.3; 100)	428.6 (328.4; 559.2)
	Post booster <sup>(1)</sup>	139	100% (97.4; 100)	3144.7 (2636.9; 3750.4)	59	100% (93.9; 100)	9015.6 (7045.2; 11537.1)
Y	Post dose 1 <sup>(1)</sup>	163	98.8% (95.6; 99.9)	1469.9 (1186.5; 1821.0)	52	92.3% (81.5; 97.9)	194.8 (117.6; 322.9)
	Pre Booster	131	88.5% (81.8; 93.4)	106.4 (76.4; 148.1)	61	98.4% (91.2; 100)	389.2 (292.3; 518.1)
	Post booster <sup>(1)</sup>	139	100% (97.4; 100)	2748.6 (2301.4; 3282.6)	69	100% (94.8; 100)	5977.6 (4746.8; 7527.6)

The analysis of immunogenicity was conducted on the primary according-to-protocol (ATP) cohort for immunogenicity.

\*rSBA testing performed at Public Health England (PHE) laboratories in UK

\*\*hSBA tested at Neomed, Laval, Canada

<sup>(1)</sup> blood sampling performed 1 month post vaccination

Serum bactericidal activity was also measured using hSBA as a secondary endpoint. Although similar responses to groups A and C were observed with both dosing schedules, a single primary dose in infants at 6 months was associated with lower hSBA responses to groups W-135 and Y as measured by the percentage of subjects with hSBA titres  $\geq 8$  [87.2% (95% CI: 74.3, 95.2) and 92.3% (95% CI: 81.5, 97.9), respectively] compared with three primary doses at 2, 4, and 6 months of age [100% (95% CI: 96.6, 100) and 100% (95% CI: 97.1, 100), respectively] (see Section 4.4 Special warnings and precautions for use ). After a booster dose, the hSBA titres to all four serogroups were comparable between the two dosing schedules.

## Toddlers

### *Immunogenicity in toddlers aged 12-23 months*

In clinical studies MenACWY-TT-039 and MenACWY-TT-040, the immune response to vaccination with either one dose of NIMENRIX or a licensed meningococcal C-CRM197 conjugate (MenC-CRM) vaccine was evaluated.

NIMENRIX elicited rSBA responses against the four meningococcal groups in both studies, with a response against group C that was comparable to the one elicited by the licensed meningococcal C-CRM<sub>197</sub> conjugate (MenC-CRM) vaccine in terms of rSBA titres  $\geq 8$  (Table 3).

**Table 3: Bactericidal antibody responses (rSBA\*) in toddlers aged 12-23 months**

Group	Response to	Study MenACWY-TT-039 <sup>(1)</sup>			Study MenACWY-TT-040 <sup>(2)</sup>		
		N	$\geq 8$ (95% CI)	GMT (95% CI)	N	$\geq 8$ (95% CI)	GMT (95% CI)
A	NIMENRIX	354	99.7% (98.4; 100)	2205 (2008; 2422)	183	98.4% (95.3; 99.7)	3170 (2577; 3899)
C	NIMENRIX	354	99.7% (98.4; 100)	478 (437; 522)	183	97.3% (93.7; 99.1)	829 (672; 1021)
	MenC-CRM	121	97.5% (92.9; 99.5)	212 (170; 265)	114	98.2% (93.8; 99.8)	691 (521; 918)
W-135	NIMENRIX	354	100% (99.0; 100)	2682 (2453; 2932)	186	98.4% (95.4; 99.7)	4022 (3269; 4949)
Y	NIMENRIX	354	100% (99.0; 100)	2729 (2473; 3013)	185	97.3% (93.8; 99.1)	3168 (2522; 3979)

The analysis of immunogenicity was conducted on the according-to-protocol (ATP) cohorts for immunogenicity.

<sup>(1)</sup> blood sampling performed 42 to 56 days post vaccination

<sup>(2)</sup> blood sampling performed 30 to 42 days post vaccination

\* tested at GSK laboratories

N = number of subjects with available results

GMT = geometric mean antibody titre

In study MenACWY-TT-039, serum bactericidal activity was also measured using hSBA as a secondary endpoint (Table 4).

**Table 4: Bactericidal antibody responses (hSBA\*) in toddlers aged 12-23 months**

Group	Response to	N	Study MenACWY-TT-039 <sup>(1)</sup>	
			$\geq 8$ (95% CI)	GMT (95% CI)
A	NIMENRIX	338	77.2% (72.4; 81.6)	19.0 (16.4; 22.1)
C	NIMENRIX	341	98.5% (96.6; 99.5)	196 (175; 219)
	MenC-CRM	116	81.9% (73.7; 88.4)	40.3 (29.5; 55.1)
W-135	NIMENRIX	336	87.5% (83.5 ; 90.8)	48.9 (41.2; 58.0)
Y	NIMENRIX	329	79.3% (74.5; 83.6)	30.9 (25.8; 37.1)

The analysis of immunogenicity was conducted on ATP cohort for immunogenicity.

<sup>(1)</sup> blood sampling performed 42 to 56 days post vaccination

\* tested at GSK laboratories

N = number of subjects with available results

GMT = geometric mean antibody titre

In Study MenACWY-TT-104, the immune response following one or two doses of NIMENRIX given 2 months apart was evaluated one month and one year after the last vaccination. NIMENRIX elicited bactericidal responses against all four groups that were similar in terms of % with rSBA titre  $\geq 8$  and GMT after one or two doses (Table 5).

**Table 5: Bactericidal antibody responses (rSBA\*) in toddlers aged 12-14 months**

Meningo-coccal Group	Vaccine Group	Timing	Study MenACWY-TT-104 <sup>(1)</sup>		
			N	$\geq 8$ (95% CI)	GMT (95% CI)
A	Nimenrix 1 dose	1 Month Post dose 1	180	97.8% (94.4; 99.4)	1437.0 (1118.3; 1846.6)
		1 Year Post dose 1	167	63.5% (55.7; 70.8)	62.7 (42.6; 92.2)
	Nimenrix 2 doses	1 Month Post dose 1	158	96.8% (92.8; 99.0)	1275.2 (970.5; 1675.4)
		1 Month Post dose 2	150	98.0% (94.3; 99.6)	1176.3 (921.8; 1501)
		1 Year Post dose 2	143	70.6% (62.4; 77.9)	76.6 (50.7; 115.7)
C	Nimenrix 1 dose	1 Month Post dose 1	179	95.0% (90.7; 97.7)	452.3 (345.6; 591.9)
		1 Year Post dose 1	167	49.1% (41.3; 56.9)	16.2 (12.4; 21.1)
	Nimenrix 2 doses	1 Month Post dose 1	157	95.5% (91.0; 98.2)	369.3 (280.9; 485.5)
		1 Month Post dose 2	150	98.7% (95.3; 99.8)	639.1 (521.8; 782.9)
		1 Year Post dose 2	143	55.2% (46.7; 63.6)	21.2 (15.6; 28.9)
W-135	Nimenrix 1 dose	1 Month Post dose 1	180	95.0% (90.8; 97.7)	2120.2 (1601.0; 2807.8)
		1 Year Post dose 1	167	65.3% (57.5; 72.5)	57.2 (39.9; 82.0)
	Nimenrix 2 doses	1 Month Post dose 1	158	94.9% (90.3; 97.8)	2030.1 (1510.7; 2728.2)
		1 Month Post dose 2	150	100% (97.6; 100)	3533.0 (2914.5; 4282.7)
		1 Year Post dose 2	143	77.6% (69.9; 84.2)	123.1 (82.7; 183.4)
Y	Nimenrix 1 dose	1 Month Post dose 1	180	92.8% (88.0; 96.1)	951.8 (705.0; 1284.9)
		1 Year Post dose 1	167	73.1% (65.7; 79.6)	76.8 (54.2; 109.0)
	Nimenrix 2 doses	1 Month Post dose 1	157	93.6% (88.6; 96.9)	933.3 (692.3; 1258.3)

Meningo-coccal Group	Vaccine Group	Timing	Study MenACWY-TT-104 <sup>(1)</sup>		
			N	≥8 (95% CI)	GMT (95% CI)
		1 Month Post dose 2	150	99.3% (96.3; 100)	1133.6 (944.5; 1360.5)
		1 Year Post dose 2	143	79.7% (72.2; 86.0)	112.3 (77.5; 162.8)

The analysis of immunogenicity was conducted on the according-to-protocol (ATP) cohort for immunogenicity

<sup>(1)</sup> blood sampling performed 21-48 days post vaccination and 44-60 weeks post vaccination

\*tested at Public Health England laboratories

In the study MenACWY-TT-104, the serum bactericidal activity was also measured using hSBA as a secondary endpoint. In terms of % with hSBA titre ≥8, at one month post vaccination, responses against groups W-135 and Y were higher after two doses of Nimenrix than after one dose, while responses against groups A and C were similar in the two groups. At one year post vaccination, the % responses with hSBA titre ≥1:8 for groups A, C, W-135 and Y were similar in both the one and two dose groups (Table 6).

**Table 6: Bactericidal antibody responses (hSBA\*) in toddlers aged 12-14 months**

Meningococcal Group	Vaccines group	Timing	Study MenACWY-TT-104 <sup>(1)</sup>		
			N	≥8 (95% CI)	GMT (95% CI)
A	Nimenrix 1 dose	1 Month Post dose 1	74	95.9% (88.6; 99.2)	118.0 (86.8; 160.5)
		1 Year Post dose 1	70	35.7% (24.6; 48.1)	6.1 (4.1; 8.9)
	Nimenrix 2 doses	1 Month Post dose 1	66	97.0% (89.5; 99.6)	132.9 (98.1; 180.1)
		1 Month Post dose 2	66	97.0% (89.5; 99.6)	170.5 (126.2; 230.2)
		1 Year Post dose 2	62	35.5% (23.7; 48.7)	6.4 (4.2; 10.0)
C	Nimenrix 1 dose	1 Month Post dose 1	78	98.7% (93.1; 100)	151.9 (104.8; 220.4)
		1 Year Post dose 1	71	80.3% (69.1; 88.8)	35.2 (22.5; 55.2)
	Nimenrix 2 doses	1 Month Post dose 1	70	95.7% (88.0; 99.1)	160.8 (109.8; 235.5)
		1 Month Post dose 2	69	100% (94.8; 100)	1753.3 (1277.7; 2404.2)
		1 Year Post dose 2	63	90.5% (80.4; 96.4)	73.4 (47.5; 113.4)
W-135	Nimenrix 1 dose	1 Month Post dose 1	72	62.5% (50.3; 73.6)	27.5 (16.1; 46.8)
		1 Year Post dose 1	72	95.8% (88.3; 99.1)	209.0 (149.9; 291.4)
	Nimenrix 2 doses	1 Month Post dose 1	61	68.9% (55.7; 80.1)	26.2 (16.0; 43.0)

Meningococcal Group	Vaccines group	Timing	Study MenACWY-TT-104 <sup>(1)</sup>		
			N	≥8 (95% CI)	GMT (95% CI)
Y		1 Month Post dose 2	70	97.1% (90.1; 99.7)	756.8 (550.1; 1041.3)
		1 Year Post dose 2	65	98.5% (91.7; 100.0)	232.6 (168.3; 321.4)
		1 Month Post dose 1	71	67.6% (55.5; 78.20)	41.2 (23.7; 71.5)
	Nimenrix 1 dose	1 Year Post dose 1	62	91.9% (82.2; 97.3)	144.4 (97.2; 214.5)
		1 Month Post dose 1	56	64.3% (50.4; 76.6)	31.9 (17.6; 57.9)
		1 Month Post dose 2	64	95.3% (86.9; 99.0)	513.0 (339.4; 775.4)
Nimenrix 2 doses	1 Year Post dose 2	58	87.9% (76.7; 95.0)	143.9 (88.5; 233.8)	

The analysis of immunogenicity was conducted on the according-to-protocol (ATP) cohort for immunogenicity

<sup>(1)</sup> blood sampling performed 21-48 days post vaccination and 44-60 weeks post vaccination

\*tested at GSK laboratories

## Children

### *Immunogenicity in children aged 2-10 years*

In two comparative studies of non-inferiority conducted in subjects aged 2-10 years, one dose of NIMENRIX was compared to either the licensed GlaxoSmithKline Biologicals' plain polysaccharide meningococcal groups A, C, W-135, Y (ACWY-PS) vaccine (study MenACWY-TT-038 ) or a licensed MenC-CRM vaccine (study MenACWY-TT-081).

In the MenACWY-TT-038 study, NIMENRIX was demonstrated to be non-inferior to the licensed ACWY-PS vaccine in terms of vaccine response to the four groups (A, C, W-135 and Y) (Table 7).

**Table 7: Bactericidal antibody responses (rSBA\*) to NIMENRIX compared with ACWY-PS vaccine in children aged 2-10 years 1 month after vaccination (study MenACWY-TT-038)**

Group	NIMENRIX			ACWY-PS vaccine		
	N	VR (95% CI)	GMT (95% CI)	N	VR (95% CI)	GMT (95% CI)
A	594	89.1% (86.3; 91.5)	6343 (5998; 6708)	192	64.6% (57.4; 71.3)	2283 (2023; 2577)
C	691	96.1% (94.4; 97.4)	4813 (4342; 5335)	234	89.7% (85.1; 93.3)	1317 (1043; 1663)
W-135	691	97.4% (95.9; 98.4)	11543 (10873; 12255)	236	82.6% (77.2; 87.2)	2158 (1815; 2565)
Y	723	92.7% (90.5; 94.5)	10825 (10233; 11452)	240	68.8% (62.5; 74.6)	2613 (2237; 3052)

The analysis of immunogenicity was conducted on ATP cohort for immunogenicity.

VR: vaccine response, defined as rSBA titres ≥ 32 for initially seronegative subjects or at least a 4-fold increase in rSBA titres from pre- to post-vaccination for initially seropositive subjects

\* tested at GSK laboratories

N = number of subjects with available results

GMT = geometric mean antibody titre

In the MenACWY-TT-081 study, NIMENRIX (N=268) was demonstrated to be non-inferior to a licensed MenC-CRM vaccine (N=92) in 2 to 10 year olds in terms of group C vaccine response one month post-vaccination [94.8% (95% CI: 91.4; 97.1) and 95.7% (95% CI: 89.2; 98.8) respectively]. Group C geometric mean titres (GMTs) were lower for the NIMENRIX group [2795 (95% CI: 2393; 3263)] versus the MenC-CRM group [5292 (95% CI: 3815; 7340)].

## Adolescents and Adults

### *Immunogenicity in adolescents aged 11-17 years and adults aged over 18 years*

In two clinical studies, one dose of NIMENRIX was compared to one dose of ACWY-PS vaccine administered to adolescents aged 11-17 years (study MenACWY-TT-036) and in adults aged 18-55 years (study MenACWY-TT-035).

In both adolescents and adults, NIMENRIX was demonstrated to be immunologically non-inferior to the ACWY-PS vaccine in terms of vaccine response. The antibody response to the four meningococcal groups elicited by NIMENRIX was either similar or higher than those elicited by the ACWY-PS vaccine (Table 8).

**Table 8: Bactericidal antibody responses (rSBA\*) to NIMENRIX compared with ACWY-PS vaccine in adolescents aged 11-17 years and adults aged over 18 years 1 month after vaccination**

Study (Age range)	Group	NIMENRIX			ACWY-PS vaccine		
		N	VR (95%CI)	GMT (95%CI)	N	VR (95%CI)	GMT (95%CI)
MenACWY- TT-036 (11-17 years)	A	553	85.4% (82.1; 88.2)	5928 (5557; 6324)	191	77.5% (70.9; 83.2)	2947 (2612; 3326)
	C	642	97.4% (95.8; 98.5)	13110 (11939; 14395)	211	96.7% (93.3; 98.7)	8222 (6807; 9930)
	W-135	639	96.4% (94.6; 97.7)	8247 (7639; 8903)	216	87.5% (82.3; 91.6)	2633 (2299; 3014)
	Y	657	93.8% (91.6; 95.5)	14086 (13168; 15069)	219	78.5% (72.5; 83.8)	5066 (4463; 5751)
MenACWY- TT-035 (18-55 years)	A	743	80.1% (77.0; 82.9)	3625 (3372; 3897)	252	69.8% (63.8; 75.4)	2127 (1909; 2370)
	C	849	91.5% (89.4; 93.3)	8866 (8011; 9812)	288	92.0% (88.3; 94.9)	7371 (6297; 8628)
	W-135	860	90.2% (88.1; 92.1)	5136 (4699; 5614)	283	85.5% (80.9; 89.4)	2461 (2081; 2911)
	Y	862	87.0% (84.6; 89.2)	7711 (7100; 8374)	288	78.8% (73.6; 83.4)	4314 (3782; 4921)

The analysis of immunogenicity was conducted on ATP cohorts for immunogenicity.

VR: vaccine response, defined as rSBA titres  $\geq 32$  for initially seronegative subjects or at least a 4-fold increase in rSBA titres from pre- to post-vaccination for initially seropositive subjects

\* tested at GSK laboratories

N = number of subjects with available results

GMT = geometric mean antibody titre



In a separate study (MenACWY-TT-085) a single dose of Nimenrix was administered to 194 Lebanese adults 56 years of age and older (including 133 aged 56-65 years and 61 aged > 65 years). The percentage of subjects with rSBA titres (measured at GSK's laboratories)  $\geq$  128 before vaccination ranged from 45% (group C) to 62% (group Y). Overall, at one month post-vaccination the percentage of vaccines with rSBA titres  $\geq$  128 ranged from 93% (group C) to 97% (group Y). In the subgroup aged > 65 years the percentage of vaccines with rSBA titres  $\geq$  128 at one month post-vaccination ranged from 90% (group A) to 97% (group Y).

### **Persistence of immune response**

The persistence of the immune response elicited by NIMENRIX was evaluated up to 5 years after vaccination in subjects aged 12 months to 55 years at the time of vaccination.

In all age groups at all persistence time-points measured, the rSBA GMTs remained higher than prior to vaccination for the four groups (A, C, W-135, Y).

The antibodies elicited by NIMENRIX were similar or higher than those induced by the licensed comparator meningococcal vaccines (Tables 9 to 14).

In contrast to the observed rSBA-MenA persistence across age groups, there was a more rapid waning (as measured at 12 months post-dose onwards) of serum bactericidal antibody titres against MenA than against other groups (C, W-135, Y) when using human complement in the assay (Tables 8, 9, 10, 11, and 13). This rapid waning of hSBA-MenA antibodies has also been observed with other meningococcal vaccines. The clinical relevance of the rapid waning of hSBA-MenA antibody titres is unknown (see Section 4.4 Special warnings and precautions for use).

### **Toddlers**

#### *Persistence of immune response in toddlers aged 12-23 months at vaccination*

In children vaccinated at toddler age, the persistence of the immune response was evaluated by rSBA and hSBA up to four years in study MenACWY-TT-048 (Table 9) and up to five years in study MenACWY-TT-032 (Table 10).

**Table 9: Four years persistence data in toddlers aged 12-23 months at vaccination (study MenACWY-TT-048)**

Group	Response to	Time-point (Years)	rSBA*			hSBA**		
			N	$\geq$ 8 (95%CI)	GMT (95%CI)	N	$\geq$ 8 (95%CI)	GMT (95%CI)
A	NIMENRIX	3	262	59.9% (53.7; 65.9)	19.3 (15.7; 23.6)	251	35.9% (29.9; 42.1)	5.8 (4.8; 7.0)
		4	224	74.1% (67.9; 79.7)	107 (77.6; 148)	198	28.8% (22.6; 35.6)	4.9 (4.0; 6.0)
C	NIMENRIX	3	262	35.9% (30.1; 42.0)	9.8 (8.1; 11.7)	253	78.3% (72.7; 83.2)	37.8 (29.4; 48.6)
		4	225	40.4% (34.0; 47.2)	12.3 (9.8; 15.3)	209	73.2% (66.7; 79.1)	32.0 (23.8; 43.0)
	MenC-CRM vaccine	3	46	13.0% (4.9; 26.3)	5.7 (4.2; 7.7)	31	41.9% (24.5; 60.9)	6.2 (3.7; 10.3)
		4	45	35.6% (21.9; 51.2)	13.5 (7.4; 24.5)	32	46.9% (29.1; 65.3)	11.3 (4.9; 25.6)
W-135	NIMENRIX	3	261	49.8% (43.6; 56.0)	24.9 (19.2; 32.4)	254	82.3% (77.0; 86.8)	52.0 (41.4; 65.2)
		4	225	49.3% (42.6; 56.1)	30.5 (22.4; 41.5)	165	80.6% (73.7; 86.3)	47.1 (35.7; 62.2)

Y	NIMENRIX	3	262	53.8% (47.6; 60.0)	22.3 (17.6; 28.4)	250	72.0% (66.0; 77.5)	33.2 (25.9; 42.5)
		4	225	58.2% (51.5; 64.7)	36.2 (27.1; 48.4)	130	65.4% (56.5; 73.5)	29.8 (20.2; 44.1)

The analysis of immunogenicity was conducted on ATP cohort for persistence adapted for each time-point.

\* rSBA testing performed at Health Protection Agency (HPA) laboratories in UK

\*\* tested a GSK laboratories

N = number of subjects with available results

GMT = geometric mean antibody titre

**Table 10: Five years persistence data in toddlers aged 12-23 months at vaccination (study MenACWY-TT-032)**

Group	Response to	Time-point (Years)	rSBA*			hSBA**		
			N	≥8 (95%CI)	GMT (95%CI)	N	≥8 (95%CI)	GMT (95%CI)
A	NIMENRIX	4	45	64.4% (48.8; 78.1)	35.1 (19.4; 63.4)	44	52.3% (36.7; 67.5)	8.8 (5.4; 14.2)
		5	49	73.5% (58.9; 85.1)	37.4 (22.1; 63.2)	45	35.6% (21.9; 51.2)	5.2 (3.4; 7.8)
C	NIMENRIX	4	45	97.8% (88.2; 99.9)	110 (62.7; 192)	45	97.8% (88.2; 99.9)	370 (214; 640)
		5	49	77.6% (63.4; 88.2)	48.9 (28.5; 84.0)	48	91.7% (80.0; 97.7)	216 (124; 379)
	MenC-CRM vaccine	4	10	80.0% (44.4; 97.5)	137 (22.6; 832)	10	70.0% (34.8; 93.3)	91.9 (9.8; 859)
		5	11	63.6% (30.8; 89.1)	26.5 (6.5; 107)	11	90.9% (58.7; 99.8)	109 (21.2; 557)
W-135	NIMENRIX	4	45	60.0% (44.3; 74.3)	50.8 (24.0; 108)	45	84.4% (70.5; 93.5)	76.9 (44.0; 134)
		5	49	34.7% (21.7; 49.6)	18.2 (9.3; 35.3)	46	82.6% (68.6; 92.2)	59.7 (35.1; 101)
Y	NIMENRIX	4	45	62.2% (46.5; 76.2)	44.9 (22.6; 89.3)	41	87.8% (73.8; 95.9)	74.6 (44.5; 125)
		5	49	42.9% (28.8; 57.8)	20.6 (10.9; 39.2)	45	80.0% (65.4; 90.4)	70.6 (38.7; 129)

Persistence of immunogenicity was analysed using the year 5 ATP cohort.

\*rSBA testing performed at PHE laboratories in UK

\*\* tested at GSK laboratories

## Children

### *Persistence of immune response in children aged 2-10 years at vaccination*

In study MenACWY-TT-088, the persistence of the immune response was evaluated by rSBA up to 68 months after vaccination in children 2-10 years of age primed in study MenACWY-TT-081 (Table 11).

**Table 11: 68 months persistence data in children 2-10 years of age at vaccination**

Group	Response to	Time-point (months)	rSBA*			hSBA**		
			N	≥8 (95%CI)	GMT (95%CI)	N***	≥8 (95%CI)	GMT (95%CI)
A	NIMENRIX	32	193	86.5% (80.9; 91.0)	196 (144; 267)	90	25.6% (16.9; 35.8)	4.6 (3.3; 6.3)
		68	178	86.5% (80.6; 91.2)	129 (93.5; 179)	170	40.6% (33.1; 48.4)	6.9 (5.4; 8.9)
C	NIMENRIX	32	192	64.6% (57.4; 71.3)	34.8 (26.0; 46.4)	90	95.6% (89.0; 98.8)	75.9 (53.4; 108)
		68	178	39.9% (32.6; 47.5)	14.2 (10.8; 18.7)	172	75.6% (68.5; 81.8)	28.4 (21.2; 37.9)

	MenC-CRM vaccine	32	69	76.8% (65.1; 86.1)	86.5 (47.3; 158)	33	90.9% (75.7; 98.1)	82.2 (34.6; 196)
		68	61	62.3% (49.0; 74.4)	44.5 (23.7; 83.6)	57	75.4% (62.2; 85.9)	34.3 (19.0; 61.9)
W-135	NIMENRIX	32	193	77.2% (70.6; 82.9)	214 (149; 307)	86	84.9% (75.5; 91.7)	69.9 (48.2; 101)
		68	178	52.8% (45.2; 60.3)	59.2 (39.3; 89.2)	159	78.6% (71.4; 84.7)	56.7 (41.5; 77.3)
Y	NIMENRIX	32	193	81.3% (75.1; 86.6)	227 (165; 314)	91	81.3% (71.8; 88.7)	79.2 (52.5; 119)
		68	178	71.3% (64.1; 77.9)	139 (96.0; 202)	159	73.0% (65.3; 79.7)	56.3 (39.5; 80.3)

The analysis of immunogenicity was conducted on ATP cohort for persistence adapted for each time-point.

\*rSBA testing performed at PHE laboratories in UK

\*\* tested at GSK laboratories

\*\*\* at month 32, a subset of subjects have been tested for hSBA

### *Persistence of immune response in children aged 6-10 years at vaccination*

In study MenACWY-TT-028, the persistence of the immune response was evaluated by hSBA one year after vaccination in children primed at 6-10 years of age with either NIMENRIX or ACWY-PS vaccine in study MenACWY-TT-027 (Table 12).

**Table 12: 1 month post-vaccination and 1 year persistence data (hSBA\*) in children 6-10 years of age at vaccination**

Group	Response to	1 month post-vaccination			1 year persistence		
		N	≥8 (95%CI)	GMT (95%CI)	N	≥8 (95%CI)	GMT (95%CI)
A	NIMENRIX	105	80.0 % (71.1; 87.2)	53.4 (37.3; 76.2)	104	16.3% (9.8; 24.9)	3.5 (2.7; 4.4)
	ACWY-PS	35	25.7% (12.5;43.3)	4.1 (2.6;6.5)	35	5.7% (0.7;19.2)	2.5 (1.9;3.3)
C	NIMENRIX	101	89.1% (81.3;94.4)	156 (99.3;244)	105	95.2% (89.2;98.4)	129 (95.4;176)
	ACWY-PS	38	39.5% (24.0;56.6)	13.1 (5.4;32.0)	31	32.3% (16.7;51.4)	7.7 (3.5;17.3)
W-135	NIMENRIX	103	95.1% (89.0;98.4)	133 (99.9;178)	103	100% (96.5;100)	257 (218;302)
	ACWY-PS	35	34.3% (19.1;52.2)	5.8 (3.3;9.9)	31	12.9% (3.6;29.8)	3.4 (2.0;5.8)
Y	NIMENRIX	89	83.1% (73.7;90.2)	95.1 (62.4;145)	106	99.1% (94.9;100)	265 (213;330)
	ACWY-PS	32	43.8% (26.4;62.3)	12.5 (5.6;27.7)	36	33.3% (18.6;51.0)	9.3 (4.3;19.9)

The analysis of immunogenicity was conducted on ATP cohort for persistence.

\* tested at GSK laboratories

## **Adolescents and Adults**

### *Persistence of immune response in adolescents aged 11-17 years at vaccination*

In study MenACWY-TT-043, the persistence of the immune response was evaluated up to 5 years after vaccination in adolescents primed with either NIMENRIX or ACWY-PS vaccine in study MenACWY-TT-036 (Table 13). See Table 7 for the primary vaccination results from study MenACWY-TT-036.

**Table 13: 5 years persistence data (rSBA\*) in adolescents aged 11-17 years at vaccination**

Group	Time-point (Years)	NIMENRIX			ACWY-PS vaccine		
		N	≥8 (95% CI)	GMT (95% CI)	N	≥8 (95% CI)	GMT (95% CI)
A	3	449	92.9% (90.1; 95.1)	448 (381; 527)	150	82.7% (75.6; 88.4)	206 (147; 288)
	5	236	97.5 % (94.5; 99.1)	644 (531; 781)	86	93.0 (85.4; 97.4)	296 (202; 433)
C	3	449	91.1% (88.1; 93.6)	371 (309; 446)	150	86.0% (79.4; 91.1)	390 (262; 580)
	5	236	88.6 % (83.8; 92.3)	249 (194; 318)	85	87.1 (78.0; 93.4)	366 (224; 599)
W-135	3	449	82.0% (78.1; 85.4)	338 (268; 426)	150	30.0% (22.8; 38.0)	16.0 (10.9; 23.6)
	5	236	86.0% (80.9; 90.2)	437 (324; 588)	86	34.9 (24.9; 45.9)	19.7 (11.8; 32.9)
Y	3	449	93.1% (90.3; 95.3)	740 (620; 884)	150	58.0% (49.7; 66.0)	69.6 (44.6; 109)
	5	236	96.6% (93.4; 98.5)	1000 (824; 1214)	86	66.3 (55.3; 76.1)	125 (71.2; 219)

The analysis of immunogenicity was conducted on ATP cohort for persistence adapted for each time-point.

\* rSBA testing performed at PHE laboratories in UK

*Persistence of immune response in adolescents and adults aged 11-25 years at vaccination*

In study MenACWY-TT-059, the persistence of the immune response was evaluated by hSBA up to 5 years after vaccination in adolescents and adults 11-25 years of age primed in study MenACWY-TT-052. For all groups (A, C, W-135, Y), the persistence of antibodies elicited by NIMENRIX was similar or higher than those induced by the ACWY-DT vaccine (Table 14).

**Table 14: 1 month post-vaccination and 5 years persistence data (hSBA\*) in adolescents and adults 11-25 years of age at vaccination**

Group	Response to	Time-point	N	≥8 (95% CI)	GMT (95% CI)
A	NIMENRIX	Month 1	356	82.0% (77.6; 85.9)	58.7 (48.6; 70.9)
		Year 1	350	29.1% (24.4; 34.2)	5.4 (4.5; 6.4)
		Year 5	141	48.9 % (40.4; 57.5)	8.9 (6.8; 11.8)
	ACWY-DT	Month 1	107	73.8% (64.4; 81.9)	42.5 (28.5; 63.3)
		Year 1	111	31.5% (23.0; 41.0)	6.0 (4.3; 8.5)
		Year 5	45	44.4% (29.6; 60.0)	7.9 (4.8; 13.2)
C	NIMENRIX	Month 1	359	96.1% (93.5; 97.9)	532 (424; 668)
		Year 1	336	94.9% (92.0; 97.0)	172 (142; 207)
		Year 5	140	92.9% (87.3; 96.5)	94.6 (65.9; 136)
	ACWY-DT	Month 1	113	99.1% (95.2; 100)	317 (217; 462)
		Year 1	105	73.3% (63.8; 81.5)	46.7 (30.2; 72.1)
		Year 5	44	79.5% (64.7; 90.2)	30.6 (17.3; 54.4)
W-135	NIMENRIX	Month 1	334	91.0% (87.4; 93.9)	117 (96.8; 141)
		Year 1	327	98.5% (96.5; 99.5)	197 (173; 225)
		Year 5	138	87.0% (80.2; 92.1)	103 (76.3; 140)
	ACWY-DT	Month 1	96	75.0% (65.1; 83.3)	70.4 (43.7; 113)
		Year 1	107	75.7% (66.5; 83.5)	48.9 (32.5; 73.8)
		Year 5	44	84.1% (69.9; 93.4)	70.4 (37.2; 133)
Y	NIMENRIX	Month 1	364	95.1% (92.3; 97.0)	246 (208; 291)

		Year 1	356	97.8% (95.6; 99.0)	272 (237; 311)
		Year 5	142	94.4% (89.2; 97.5)	225 (174; 290)
	ACWY-DT	Month 1	111	81.1% (72.5; 87.9)	103 (67.5; 159)
		Year 1	112	86.6% (78.9; 92.3)	101 (69.6; 146)
		Year 5	44	90.9% (78.3; 97.5)	129 (77.4; 216)

The analysis of immunogenicity was conducted on ATP cohort for persistence adapted for each time-point.

\* tested at GSK laboratories

### **Immune memory**

In study MenACWY-TT-014, the induction of immune memory was assessed one month after the administration of a one fifth dose of ACWY-PS vaccine (10 µg of each polysaccharide) to children in the third year of life. These children were previously primed in study MenACWY-TT-013 with either NIMENRIX or a licensed MenC-CRM vaccine at the age of 12 to 14 months.

One month after the challenge dose, the GMTs elicited by the subjects primed with NIMENRIX increased 6.5 to 8-fold, indicating that NIMENRIX induces immune memory to all four groups A, C, W-135 and Y. The post-challenge rSBA-MenC GMT was similar in both study groups, indicating that NIMENRIX induces an analogous immune memory to group C as the licensed MenC-CRM vaccine (Table 15).

**Table 15: Immune response (rSBA\*) 1 month after a challenge vaccination in subjects primed with NIMENRIX or a MenC-CRM vaccine at the age of 12 to 14 months**

Group	Response to	Pre-challenge		Post-challenge	
		N	GMT (95%CI)	N	GMT (95%CI)
A	NIMENRIX	32	544 (325; 911)	25	3322 (2294; 4810)
C	NIMENRIX	31	174 (105; 289)	32	5966 (4128; 8621)
	MenC-CRM	28	34.4 (15.8; 75.3)	30	5265 (3437; 8065)
W-135	NIMENRIX	32	644 (394; 1052)	32	11058 (8587; 14240)
Y	NIMENRIX	32	440 (274; 706)	32	5737 (4216; 7806)

The analysis of immunogenicity was conducted on ATP cohort for immunogenicity.

\* tested at GSK laboratories

### **NIMENRIX booster vaccination after priming in toddlers, children, adolescents and adults**

For subjects primed with NIMENRIX aged 1 year and above and boosted with NIMENRIX 4 or 5 years later, more than 99.0% of all subjects achieved post-booster SBA titres  $\geq$  1:8 for both assays (studies MenACWY-TT-062, 048, 059, 088). One month after the booster vaccination, the GMTs elicited were significantly higher than those elicited by age matched naïve control groups, indicating that NIMENRIX induces immune memory to groups A, C, W-135, and Y.

The observed MenC booster response with NIMENRIX was similar to that observed in subjects primed and boosted with a monovalent MenC-CRM conjugate vaccine (study MenACWY-TT-048). One year after NIMENRIX booster, SBA titres  $\geq$  1:8 persisted in at least 95.5% of subjects (study MenACWY-TT-048, 12 to 23 months of age at primary vaccination).

When NIMENRIX was used as a booster following primary vaccination with a MenACWY-DT conjugate vaccine or a monovalent MenC conjugate vaccine (study MenACWY-TT-059, 10 to 25 years of age at primary vaccination and study MenACWY-TT-088, 2 to 10 years of age at primary vaccination), the titres increased by 48-340 fold for all groups and 100% of the subjects reached SBA titres  $\geq$  1:8.

### **Immunogenicity in subjects previously vaccinated with a plain polysaccharide meningococcal vaccine**

In study MenACWY-TT-021 conducted in subjects aged 4.5 to 34 years, the immunogenicity of NIMENRIX administered between 30 and 42 months after vaccination with an ACWY-PS vaccine was compared to the immunogenicity of NIMENRIX administered to age-matched subjects who had not been vaccinated with any meningococcal vaccine in the preceding 10 years. The rSBA GMTs were significantly lower in the subjects who had received a dose of ACWY-PS vaccine 30-42 months prior to NIMENRIX (Table 16). Clinical relevance of this observation is unknown since all subjects achieved rSBA titres  $\geq$  8 for each group (A, C, W-135, Y) regardless of meningococcal vaccination history.

**Table 16: Immune response (rSBA\*) 1 month after NIMENRIX vaccination in subjects according to their meningococcal vaccine history**

Group	Subjects vaccinated 30 to 42 months previously with ACWY-PS			Subjects who had not received a meningococcal vaccine in the preceding 10 years		
	N	$\geq$ 8 (95%CI)	GMT (95%CI)	N	$\geq$ 8 (95%CI)	GMT (95%CI)
A	146	100% (97.5; 100)	6869 (6045; 7805)	69	100% (94.8; 100)	13015 (10722; 15798)
C	169	100% (97.8; 100)	1946 (1583; 2391)	75	100% (95.2; 100)	5495 (4266; 7076)
W-135	169	100% (97.8; 100)	4636 (3942; 5451)	75	100% (95.2; 100)	9078 (7088; 11627)
Y	169	100% (97.8; 100)	7800 (6683; 9104)	75	100% (95.2; 100)	13895 (11186; 17261)

The analysis of immunogenicity was conducted on ATP cohort for immunogenicity.

\* tested at GSK laboratories

### **Response to NIMENRIX in subjects at increased risk for meningococcal infections**

Study MenACWY-TT-084 evaluated the immunogenicity of 1 and 2 doses of NIMENRIX given two months apart in 43 at-risk subjects aged 2-17 years (at increased risk for meningococcal disease, i.e., asplenic subjects, and hyposplenic subjects) compared to 43 healthy age-matched subjects.

One month after the first vaccine dose, vaccine response rates (rSBA titre  $\geq$ 1:32 or a  $\geq$ 4-fold increase in rSBA titre from baseline) for groups A, C, W, and Y, respectively, were 100%, 92.5%, 100% and 97.5% in the at-risk group and were 97.5%, 97.5%, 97.5%, and 100% for healthy subjects. After the second vaccine dose, vaccine response rates in both at-risk and healthy subjects were 100% for each of the 4 meningococcal groups.

## **5.2 Pharmacokinetic Properties**

Not applicable.

### 5.3 Preclinical Safety Data

Non-clinical data reveal no special hazard for humans based on local tolerance, acute toxicity, repeated dose toxicity, developmental/reproductive toxicity and fertility studies. The carcinogenic potential of NIMENRIX has not been investigated.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of Excipients

The powder for reconstitution contains the excipients trometamol and sucrose. The diluent contains 0.9% sodium chloride in water for injections. No preservative or adjuvant is added.

### 6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

### 6.3 Shelf Life

The shelf-life of NIMENRIX is three years from the date of manufacture when stored at temperatures between 2°C to 8°C. The expiry date of the vaccine is marked on the label and packaging. After reconstitution, the vaccine should be used promptly.

For shelf-life after reconstitution of the medicinal product (see Section 6.6 Special precautions for disposal and other handling).

### 6.4 Special Precautions for Storage

NIMENRIX must be stored between 2°C to 8°C. The sterile 0.9% saline diluent may be refrigerated or stored at ambient temperatures, but must not be frozen. The vaccine should be stored in the original package in order to protect from light.

### 6.5 Nature and Contents of Container

NIMENRIX is supplied in a glass vial (type 1 glass) with a stopper (butyl rubber), together with 0.5mL solvent either in a glass ampoule (type I glass) or a pre-filled syringe with a stopper (butyl rubber).

Pack sizes of 1 and 10 with or without separate needles.

Not all pack sizes or presentations may be marketed.

### 6.6 Special Precautions for Disposal and Other Handling


#### Instructions for reconstitution of the vaccine with the solvent presented in pre-filled syringe

NIMENRIX must be reconstituted by adding the entire contents of the pre-filled syringe of solvent to the vial containing the powder.


To attach the needle to the syringe, refer to the below picture.

Needle

Version: pfdnimev1111



nev10819  
e 23 of 25



1. Holding the syringe barrel in one hand (avoid holding the syringe plunger), unscrew the syringe cap by twisting it anticlockwise.
2. To attach a screw-thread needle to the syringe, twist the needle clockwise into the syringe until you feel it lock (see picture). A needle without a screw-thread may also be used. In this case, the needle should be attached without screwing.
3. Remove the needle protector, which on occasion can be a little stiff.
4. Add the solvent to the powder. After the addition of the solvent to the powder, the mixture should be well shaken until the powder is completely dissolved in the solvent.

The reconstituted vaccine is a clear colourless solution.

The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.

After reconstitution, the vaccine should be used promptly. Although delay is not recommended, stability has been demonstrated for 8 hours at 30°C after reconstitution. If not used within the 8 hours, do not administer the vaccine.

A new needle should be used to administer the vaccine.

Any unused product or waste material should be disposed of in accordance with local requirements.

### **Instructions for reconstitution of the vaccine with solvent presented in ampoules**

NIMENRIX must be reconstituted by adding the entire content of the ampoule of solvent to the vial containing the powder. To do so, break the top of the ampoule, draw up the solvent with a syringe and add the solvent to the powder. The mixture should be well shaken until the powder is completely dissolved in the solvent.

The reconstituted vaccine is a clear colourless solution.

The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.

After reconstitution, the vaccine should be used promptly. Although delay is not recommended, stability has been demonstrated for 8 hours at 30°C after reconstitution. If not used within 8 hours, do not administer the vaccine.

A new needle should be used to administer the vaccine.



## 7. MEDICINE SCHEDULE

Prescription medicine; except when administered to a person 16 years of age or over by a registered pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health.

## 8. SPONSOR

Pfizer New Zealand Limited  
P O Box 3998 Auckland, New Zealand, 1140.  
Toll Free Number: 0800 736 363

## 9. DATE OF FIRST APPROVAL

16 October 2014

## 10. DATE OF REVISION OF TEXT

13 November 2019

## SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
4.2	Dosage updated to include recommended dosing for infants from 6 weeks to 12 months
4.4	Addition of Immune response in infants aged 6 months to less than 12 months
4.8	Addition of details of a separate infant study (MenACWY-TT-087)
5.1	Information added to Clinical Trials section relating to Study MenACWY-TT-087

® = Registered Trade Mark

NIMENRIX® is a registered trademark of GlaxoSmithKline Biologicals SA, licensed to Pfizer Inc.